Opus Genetics (IRD) Competitors $1.09 -0.02 (-1.80%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.14 +0.05 (+4.59%) As of 02/21/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends IRD vs. ADCT, SGMT, PBYI, BMEA, CHRS, MCRB, SLDB, TELO, TIL, and KYTXShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include ADC Therapeutics (ADCT), Sagimet Biosciences (SGMT), Puma Biotechnology (PBYI), Biomea Fusion (BMEA), Coherus BioSciences (CHRS), Seres Therapeutics (MCRB), Solid Biosciences (SLDB), Telomir Pharmaceuticals (TELO), Instil Bio (TIL), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry. Opus Genetics vs. ADC Therapeutics Sagimet Biosciences Puma Biotechnology Biomea Fusion Coherus BioSciences Seres Therapeutics Solid Biosciences Telomir Pharmaceuticals Instil Bio Kyverna Therapeutics Opus Genetics (NASDAQ:IRD) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability, dividends and community ranking. Which has more volatility & risk, IRD or ADCT? Opus Genetics has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Is IRD or ADCT more profitable? ADC Therapeutics has a net margin of -300.00% compared to Opus Genetics' net margin of -324.45%. ADC Therapeutics' return on equity of 0.00% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Opus Genetics-324.45% -63.65% -56.94% ADC Therapeutics -300.00%N/A -61.33% Does the MarketBeat Community favor IRD or ADCT? ADC Therapeutics received 55 more outperform votes than Opus Genetics when rated by MarketBeat users. However, 100.00% of users gave Opus Genetics an outperform vote while only 67.44% of users gave ADC Therapeutics an outperform vote. CompanyUnderperformOutperformOpus GeneticsOutperform Votes3100.00% Underperform VotesNo VotesADC TherapeuticsOutperform Votes5867.44% Underperform Votes2832.56% Which has better earnings & valuation, IRD or ADCT? Opus Genetics has higher earnings, but lower revenue than ADC Therapeutics. Opus Genetics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpus Genetics$19.05M1.81-$9.99M-$1.09-1.00ADC Therapeutics$69.56M2.27-$240.05M-$2.39-0.68 Does the media prefer IRD or ADCT? In the previous week, Opus Genetics had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 5 mentions for Opus Genetics and 2 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.97 beat Opus Genetics' score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate IRD or ADCT? Opus Genetics currently has a consensus target price of $8.00, suggesting a potential upside of 633.94%. ADC Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 389.30%. Given Opus Genetics' higher probable upside, analysts clearly believe Opus Genetics is more favorable than ADC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in IRD or ADCT? 15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 6.6% of Opus Genetics shares are held by insiders. Comparatively, 4.1% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryADC Therapeutics beats Opus Genetics on 10 of the 17 factors compared between the two stocks. Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.04M$7.06B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-1.005.7326.0419.11Price / Sales1.81306.03447.4676.36Price / CashN/A65.6738.0134.83Price / Book0.506.717.644.62Net Income-$9.99M$138.33M$3.18B$245.85M7 Day Performance-3.54%-2.63%-2.00%-2.61%1 Month Performance0.93%-2.33%-0.44%-2.14%1 Year PerformanceN/A-5.33%16.44%12.98% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics1.9444 of 5 stars$1.09-1.8%$8.00+633.9%N/A$35.04M$19.05M-1.0014Analyst ForecastADCTADC Therapeutics2.8839 of 5 stars$1.47-3.0%$8.00+446.1%-65.1%$141.65M$69.56M-0.61310Short Interest ↓SGMTSagimet Biosciences1.8145 of 5 stars$4.56-0.2%$23.00+404.5%-38.9%$139.40M$2M0.008PBYIPuma Biotechnology3.7611 of 5 stars$2.80+0.6%$7.00+150.3%-55.5%$137.20M$243.57M5.82200Upcoming EarningsNews CoverageBMEABiomea Fusion3.3375 of 5 stars$3.76+0.2%$39.36+947.2%-77.4%$136.23MN/A-0.9450Positive NewsCHRSCoherus BioSciences3.6681 of 5 stars$1.18+4.9%$5.38+357.4%-56.9%$136.17M$257.24M-14.69330MCRBSeres Therapeutics3.9958 of 5 stars$0.80+1.8%$5.08+538.6%-23.5%$135.91M$126.33M-3.46330News CoverageSLDBSolid Biosciences4.0798 of 5 stars$3.44+19.3%$15.30+345.4%-42.4%$135.49M$8.09M-1.12100Analyst ForecastAnalyst RevisionNews CoverageGap UpHigh Trading VolumeTELOTelomir Pharmaceuticals2.2818 of 5 stars$4.45+1.8%N/A-54.8%$132.34MN/A-7.671Analyst ForecastNews CoverageTILInstil Bio2.9407 of 5 stars$20.03-3.8%$114.00+469.1%+88.3%$130.72MN/A-1.73410News CoveragePositive NewsKYTXKyverna Therapeutics1.1479 of 5 stars$3.02+0.5%$25.71+752.9%-89.9%$130.16M$7.03M0.0096 Related Companies and Tools Related Companies ADC Therapeutics Alternatives Sagimet Biosciences Alternatives Puma Biotechnology Alternatives Biomea Fusion Alternatives Coherus BioSciences Alternatives Seres Therapeutics Alternatives Solid Biosciences Alternatives Telomir Pharmaceuticals Alternatives Instil Bio Alternatives Kyverna Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IRD) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRD Stock Alerts